Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luis Mayorga has a total of 310 co-authors. Here are the top co-authors by number of shared publications:

  • Francesc Casellas

    Unitat d’Atenció Crohn Colitis (UACC), Gastroenterology Department, Vall d’Hebron University Hospital , Barcelona

    6 shared publications
  • Natalia Borruel

    Crohn’s and colitis Attention Unit. Digestive System Department, Hospital Vall d’Hebron, Barcelona, Spain

    6 shared publications
  • Chaysavanh Manichanh

    Microbiome Lab, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

    5 shared publications
  • Claudia Herrera-De Guise

    Unitat d’Atenció Crohn Colitis (UACC), Gastroenterology Department, Vall d’Hebron University Hospital , Barcelona

    4 shared publications
  • Claudia Herrera-Deguise

    Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Hospital Universitari Vall d’Hebron , Barcelona

    4 shared publications
  • Virginia Robles Alonso

    Unitat Atenció Crohn-Colitis, Digestive System Department, Hospital Universitari Vall d’Hebron , Barcelona , Spain

    4 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Distinct microbial mediators link diet to inflammation in Crohn’s disease and ulcerative colitis

    by Luis Mayorga, Arnau Noguera Segura, Laura Campderros, Marc Pons-Tarin, Zaida Soler, Sara Vega-Abellaneda, Gerard Serrano-Gomez, Claudia Herrera-Deguise, Virginia Robles-Alonso, Natalia Borruel, et al.

    Background: Inflammatory bowel disease (IBD) arises from complex interactions among diet, host and gut microbiome. Although diet influences intestinal inflammation, the microbial and metabolic pathways involved, and their differences between Crohn’s disease (CD) and ulcerative colitis (UC), the two main subtypes of IBD remain unclear. Objective: To investigate how the gut microbiome mediates the effects of habitual diet on inflammatory activity in IBD. Design: This longitudinal study included 198 adults (100 healthy controls, 49 CD, 49 UC), participants completed a validated food frequency questionnaire. Dietary quality was evaluated using established indices (Alternative Mediterranean Diet, Healthy Eating Index-2015, Índice de Alimentación Saludable, Mean Adequacy Ratio, Plant-Based Dietary Indexes, Healthy Food Diversity). Participants also provided two stool samples (baseline and 6 months). Shotgun metagenomics (n=366) enabled taxonomic and functional profiling. Causal mediation analyses were used to identify microbial features mediating the effect of diet on inflammation. Results: IBD patients exhibited lower dietary diversity, fibre intake and nutritional adequacy compared with controls. Microbiome diversity was lowest in CD, intermediate in UC and correlated positively with higher intake of fibre, fruit, vegetables and nuts, and negative with processed foods and sugary beverages. Causal mediation analyses revealed that in CD, coffee, whole wheat bread and healthier diets lowered the Harvey-Bradshaw index through specific bacterial species and metabolites. In UC, Mediterranean-like diets, fruits and coffee reduced C reactive protein via greater microbial richness, reduced dysbiosis and short-chain fatty acid-related functions. Conclusion: Diet quality influences inflammation in IBD through distinct microbiome pathways: specific taxa and metabolites mediate effects in CD, whereas microbial richness and global composition drive protection in UC.


  • Open Access

    Higher ustekinumab concentrations in induction are associated with better endoscopic outcomes in inflammatory bowel disease

    by Xavier Serra-Ruiz, Elena Céspedes-Martínez, Luis Mayorga, Claudia Herrera-Deguise, Virginia Robles, Ernesto Lastiri, Sonia Garcia-Garcia, María Larrosa-García, María Teresa Sanz-Martínez, Zahira Pérez, et al.

    Background: Evidence suggests a relationship between ustekinumab (UST) concentrations and therapeutic outcomes in inflammatory bowel disease. Objectives: This study aimed to evaluate the association between UST concentrations during the induction phase and treatment outcomes at week 24 in patients with Crohn’s disease (CD) and ulcerative colitis (UC). The primary outcome was endoscopic remission at week 24, defined as a simple endoscopic score (SES-CD) ⩽2 for CD and a Mayo endoscopic score = 0 for UC. Secondary outcomes included endoscopic response, clinical remission, and treatment persistence. Design: This was a prospective observational study assessing clinical and endoscopic outcomes in CD and UC patients starting UST therapy. Methods: Consecutive patients with CD and UC were included at the initiation of UST treatment. Trough UST concentrations were measured at weeks 8, 16, and 24 after the first intravenous dose, and the main outcomes were assessed at week 24. Endoscopic and clinical parameters were used to evaluate treatment efficacy and persistence. Results: Seventy patients (45 with CD) were enrolled. Those achieving endoscopic remission and response at week 24 had higher UST levels at week 8 (4.5 vs 2.6 μg/mL, p = 0.0028; 4.1 vs 2.4 μg/mL, p = 0.0024, respectively). Patients with UST concentrations in the fourth quartile (Q4) at week 8 (>4.5 μg/mL) had higher rates of endoscopic remission (66.7% (Q4) vs 20% (Q1); 33.3% (Q2); 28.6% (Q3); p = 0.012). A UST concentration threshold of 4.5 μg/mL at week 8 was the best predictor of endoscopic remission (AUC = 0.7, sensitivity 54.5%, specificity 83.8%), while 3.5 μg/mL predicted endoscopic response (AUC = 0.732, sensitivity 53.8%, specificity 87%). Longer disease duration correlated with a higher risk of UST discontinuation (odds ratio, 1.034, 95% confidence interval, 1.002–1.068, p = 0.035). Higher UST concentrations in Q4 did not result in greater drug persistence ( p = 0.319). Conclusion: UST concentrations at week 8 were positively associated with endoscopic outcomes at week 24, with a threshold of 4.5 μg/mL reliably predicting endoscopic remission. Further randomized clinical trials are warranted to explore whether optimizing UST treatment based on post-induction concentrations can enhance therapeutic outcomes.

  • Open Access

    Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients

    by Luis Mayorga Ayala, Claudia Herrera-Deguise, Juliana Esperalba, Xavier Martinez-Gomez, Elena Céspedes Martinez, Xavier Serra Ruiz, Virginia Robles, Ernesto Lastiri, Zahira Perez, Elena Oller, et al.

    Background: Studies investigating the long-term cellular immune response to SARS-CoV-2 mRNA vaccines in patients with inflammatory bowel disease (IBD) remain limited, particularly among those receiving immunosuppressive therapy. Methods: We prospectively evaluated humoral and cellular immune responses at short-term (4–6 weeks) and long-term (6–12 months) time points following SARS-CoV-2 mRNA vaccination in patients with IBD receiving anti-TNF agents, thiopurines, or combination therapy. We defined the short-term response as the measurement taken 4–6 weeks after the second vaccine dose and the long-term response as the measurement taken between 6 and 12 months after the first determination. A cohort of healthy controls was included for short-term comparative analysis. Results: At long-term follow-up, quantitative humoral responses were reduced in patients receiving anti-TNF monotherapy. In contrast, a reduced quantitative cellular response was found in the thiopurine (median 0.7 UI/mL, p < 0.05) and anti-TNF combo groups (median 0.4 UI/mL, p < 0.01) compared to anti-TNF monotherapy (median 2.2 UI/mL). Conclusions: There was a robust long-term humoral and cellular response to vaccination, but a diminished quantitative cellular response in patients treated with thiopurines or combo therapy compared to anti-TNF monotherapy.


  • Open Access

    Dashboard-Guided Anti-TNF Induction: An Effective Strategy to Minimize Immunogenicity While Avoiding Immunomodulators—A Single-Center Cohort Study

    by Elena Céspedes-Martínez, Virginia Robles-Alonso, Xavier Serra-Ruiz, Claudia Herrera-De Guise, Luis Mayorga-Ayala, Sonia García-García, María Larrosa-García, Francesc Casellas, Natalia Borruel

    Background: Proactive therapeutic drug monitoring facilitates early dose optimization to prevent primary and secondary failure to antitumor necrosis factor (TNF). We aimed to investigate the impact of dashboard-guided induction dosing strategy on anti-TNF durability and immunogenicity. Methods: We conducted a single-center cohort analysis of patients with Crohn’s disease (CD) and Ulcerative colitis (UC) who initiated treatment with infliximab or adalimumab between January 2020 and March 2023. Induction was prospectively personalized using a pharmacokinetic model-guided dosing strategy, with drug measurements at week 2, 6, and 14, and the first dose adjustment occurred in week 4. Data were recorded retrospectively. We assessed treatment durability, pharmacokinetic outcomes, clinical remission (CR), and endoscopic remission (ER), at both weeks 24 and 56. Multivariate analysis and Kaplan–Meier curves were used to compare outcomes. Results: We enrolled 147 patients (92 CD /55 UC). Anti-TNF drug survival probability was 85.00% after a year. Seventy-seven percent of patients were prescribed an intensified dose in the first year, which was associated with improved drug durability. Only 1 patient out of 147 developed antibodies to adalimumab, none to infliximab. After 24 and 52 weeks of treatment 92.5% (136/147) and 72.78% (107/147) of patients achieved CR, respectively. ER was observed in 59.39% (79/133) of patients. The use of immunomodulators or carriage of HLA DQA1*05 variant was not associated with adverse treatment or pharmacokinetic outcomes. Conclusions: Optimizing anti-TNF induction with a dashboard-guide dosing strategy proves to be a valuable approach to enhance treatment durability and clinical outcomes in inflammatory bowel disease patients. Immunogenicity appears to be mitigated by the model, which even mitigates the impact of immunomodulators and overcomes HLA DQA1*05 effect.


  • Open Access

    Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology

    by Gerard Serrano-Gómez, Francisca Yañez, Zaida Soler, Marc Pons-Tarin, Luis Mayorga, Claudia Herrera-Deguise, Natalia Borruel, Antonio Rodriguez-Sinovas, Marta Consegal, Isaac Manjón, et al.

    Background: The gut microbiome plays a key role in the development of inflammatory bowel disease (IBD), as imbalances in microbial composition are associated with immune dysfunction. However, the specific mechanisms by which certain microorganisms contribute to this process remain unclear. Methods: Here, we employed a multi-omics approach on fecal samples to identify novel microbiome markers and elucidate mechanisms underlying IBD. Shotgun metagenomics was applied to 212 samples (850 in total with validation cohort), shotgun metatranscriptomics to 103 samples and metabolomics to 105 samples. Machine learning techniques were used to predict disease and the three omics data were integrated to propose a mechanistic role of the microbiota. Results: Metagenomic analysis identified Crohn's disease (CD)-specific microbiome signatures, including a panel of 20 species that achieved a high diagnostic performance, with an area under the ROC curve (AUC) of 0.94 in an external validation set. Metatranscriptomic analysis revealed significant alterations in microbial fermentation pathways in CD, but not in ulcerative colitis (UC), highlighting disruptions that explain the depletion of butyrate—a key anti-inflammatory metabolite—observed in metabolomics analysis. Integrative multi-omics analyses further identified active virulence factor genes in CD, predominantly originating from the adherent-invasive Escherichia coli (AIEC). Notably, these findings unveiled novel mechanisms, including E. coli-mediated aspartate depletion and the utilization of propionate, which drives the expression of the ompA virulence gene, critical for bacterial adherence and invasion of the host’s macrophages. Interestingly, these microbiome alterations were absent in UC, underscoring distinct mechanisms of disease development between the two IBD subtypes. Conclusions: In conclusion, our study not only identifies promising novel biomarkers with strong diagnostic potential, which could be valuable in challenging clinical scenarios, but also offers an integrated multi-omics perspective on the microbial mechanisms underlying inflammation and virulence in Crohn's disease.


  • Open Access

    Leishmaniasis in Patients With Inflammatory Bowel Disease: A National Multicenter Study of GETECCU

    by L Madero‐Velázquez, A Mínguez, L Mayorga, Jj Ramírez, N Moreno, C Amorós, Ma Nieto, R Mena, Jm Benítez, L Gimeno‐Pitarch, et al.

    Background: Leishmaniasis (LI) is a vector‐borne illness caused by a protozoan of the genus Leishmania . Data on the features of LI in patients with inflammatory bowel disease (IBD) are scarce. Aim: To describe the characteristics of patients with IBD who present with leishmaniasis, infection outcomes and the risk factors associated with developing visceral leishmaniasis (VL). Methods: An observational retrospective study performed in 26 hospitals in Spain, including all adult patients with IBD who developed Leishmaniasis from 2012 to 2022. Results: A total of 73 patients were included [mean age 48 years; 65% male; 68% Crohn's disease]. Sixty patients (82.2%) presented localized cutaneous Leishmaniasis (CL), 2 (2.7%) diffuse CL, 3 (4.1%) mucocutaneous Leishmaniasis (MCL) and 8 (11%) VL. All patients were under biologicals (69 [94.5%]) or immunosuppressants (IMM) (4 [5.5%]) at Leishmaniasis diagnosis. AntiTNF was used in 97%, while 2 patients (3%) were receiving ustekinumab. Leishmaniasis resolution was achieved by 48% and 96% of the patients after 1 and 12 months, respectively. Biological withdrawal after Leishmaniasis diagnosis was not statistically related to increased rates of infection resolution among patients with localized CL. Age was the only risk factor associated with VL (OR 1.2, 95%CI 1.04–1.39; p = 0.012). Conclusions: Leishmaniasis in patients with IBD doesn't seem to follow a complicated clinical course, even in those with localized CL who do not discontinue biological therapy after infection diagnosis. Age might be a risk factor for developing VL. This infection should be considered for immunosuppressed patients with IBD and suggestive symptoms dwelling or travelling to endemic areas.


  • Gut Microbiota Composition in Long-Remission Ulcerative Colitis is Close to a Healthy Gut Microbiota

    by Claudia Herrera-Deguise, Encarna Varela, Guillaume Sarrabayrouse, Marta Pozuelo del Río, Virginia Robles Alonso, Natalia Borruel Sainz, Francesc Casellas, Luis Fernando Mayorga, Chaysavanh Manichanh, Fernando Azpiroz Vidaur, et al.

    Background: Microbiome studies report low gut microbial richness and diversity in ulcerative colitis (UC) patients. We explored whether UC patients who reach long-term clinical, endoscopic, and histological remission show a gut microbial ecosystem that is similar to healthy individuals. Methods: We collected 184 stool samples from 111 individuals (UC patients in long remission, short remission, flare, and healthy control subjects). Microbiota was analyzed by amplicon sequencing (16S ribosomal RNA) and quantitative polymerase chain reaction for specific taxa. All UC remission patients were followed-up for 2 years. Findings: A drop in species diversity and richness, underrepresentation of butyrate producers, and gain of potentially harmful bacteria were significantly detected in samples from disease-flare and short-remission patients. In contrast, Chao1 and Shannon indexes of diversity did not differ among patients in long remission and healthy control subjects. Long-remission patients also presented fecal bacterial composition closer to that in healthy control subjects. There was a positive correlation between Akkermansia muciniphila abundance and time in remission (rs = 0.53, P < .001). Logistic regression analysis showed that a high Shannon index (odds ratio, 4.83; 95% confidence interval, 1.5-20.6) or presence of A. muciniphila (odds ratio, 4.9; 95% confidence interval, 1.12-29.08) in fecal samples at entry was independently associated with clinical remission over a follow-up period of 24 months. Interpretation: UC patients who achieve long-term remission show evidence of substantial recovery of the gut microbial ecosystem in terms of diversity and composition. Recovery may just reflect adequate control of inflammatory activity, but higher bacterial diversity or the presence of A. muciniphila in fecal samples predicts flare-free outcomes.


  • : SEVERE AND REFRACTORY GASTROINTESTINAL TOXICITY DUE TO IMMUNE CHECKPOINT INHIBITORS: CLINICAL EXPERIENCE IN A TERTIARY REFERRAL HOSPITAL

    by Elena Céspedes Martínez, Virginia Robles Alonso, Claudia Herrera-De Guise, Luis Mayorga, Francesc Casellas, María Roca-Herrera, Natalia Borruel

    This text discusses a study conducted on the use of immune checkpoint inhibitors (ICI) and focused on the severe gastrointestinal toxicities that can occur as a result of the treatment. The study included 18 adult patients who were referred to a Gastrointestinal Unit for severe toxicities between January 2017 and January 2020. The toxicities observed were enterocolitis, microscopic colitis, and gastritis. The study found that stopping ICI treatment and initiating steroid treatment led to clinical remission in most patients. However, some patients required additional treatments such as anti-TNF drugs without as good results as reported previously. Authors found Ustekinumab a good option of treatment in refractory to anti-TNF patients. Other treatment options are Granulocyte-apheresis and Vedolizumab. Moreover, clinicians need to start prophylactic antibiotics and antifungal therapies to prevent treatment related complications. It is important to create multidisciplinary committees to aid the clinicians and oncologists should refer patients to an experienced Gastroenterology Unit. IBD patients under ICI treatment should be monitored in their IBD units. Gastrointestinal immune-related adverse events are becoming increasingly common in daily practice, and gastroenterologists play a critical role in managing these patients. Introduction: immune checkpoint inhibitors (ICI) are increasingly used to treat several types of cancer. These drugs lead to a wide range of toxicities. Immune-related gastrointestinal adverse events are common and potentially severe. In this manuscript, we recount the real clinical experience in a tertiary center. Methods: a retrospective and observational study was conducted in adult patients under ICI treatment. Included patients had been referred to the Gastrointestinal Service of Hospital Universitario Vall d'Hebron for evaluation of severe toxicities, from January 2017 to January 2020, for whom the clinical, epidemiological and evolutive data were collected. Results: a total of 18 patients were included. Fifty-five percent received anti-programmed cell death protein 1 (PD-1)/anti-programmed death-ligand 1 (anti PD-L1), 11 % received anti- cytotoxic T lymphocyte antigen 4 (CTLA-4) and 33 % received both treatments. The toxicities were manifested as enterocolitis, microscopic colitis and gastritis. Upper gastrointestinal endoscopy was performed in seven patients; all were proved to have histological changes on duodenum biopsies. Treatment was stopped in all patients and steroids were initiated. Sixty-six per cent achieved clinical remission with steroids. Five patients received anti-TNF treatment (infliximab). Only one of the five had responded. Two anti-TNF refractory patients received ustekinumab, with an appropriate clinical response. One patient received apheresis granulocyte as concomitant treatment. A patient with a steroid-dependent course started vedolizumab. Three patients had other immune-related adverse events. Conclusion: gastrointestinal immune-related adverse events are acquiring a higher profile in daily practice and gastroenterologists play an even greater role in the management of these patients.


  • Open Access

    Intercontinental Gut Microbiome Variances in IBD

    by Luis Mayorga, Gerard Serrano-Gómez, Zixuan Xie, Natalia Borruel, Chaysavanh Manichanh

    The development of biomarkers for inflammatory bowel disease (IBD) diagnosis would be relevant in a generalized context. However, intercontinental investigation on these microbial biomarkers remains scarce. We examined taxonomic microbiome variations in IBD using published DNA shotgun metagenomic data. For this purpose, we used sequenced data from our previous Spanish Crohn’s disease (CD) and ulcerative colitis (UC) cohort, downloaded sequence data from a Chinese CD cohort, and downloaded taxonomic and functional profiling tables from a USA CD and UC cohort. At the global level, geographical location and disease phenotype were the main explanatory covariates of microbiome variations. In healthy controls (HC) and UC, geography turned out to be the most important factor, while disease intestinal location was the most important one in CD. Disease severity correlated with lower alpha-diversity in UC but not in CD. Across geography, alpha-diversity was significantly different independently of health status, except for CD. Despite recruitment from different countries and with different disease severity scores, CD patients may harbor a very similar microbial taxonomic profile. Our study pointed out that geographic location, disease activity status, and other environmental factors are important contributing factors in microbiota changes in IBD. We therefore strongly recommend taking these factors into consideration for future IBD studies to obtain globally valid and reproducible biomarkers.


  • Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak

    by Claudia Herrera-De Guise, Luis Fernando Mayorga Ayala, Xavier Serra Ruiz, Virginia Robles Alonso, Natalia Borruel Sainz, Arantxa Ibarz, Zahira Pérez Martínez, Francesc Casellas

    Background and aims: inflammatory bowel disease (IBD) affects many aspects of a patient's life and impairs their health-related quality of life (HRQoL). The COVID-19 out-break has led to important mobility restrictions and a dra-matic re-adjustment of social habits and health systems. This study aimed to assess the influence of the outbreak and mo-bility restrictions on the HRQoL of IBD patients with stable clinical remission on biologic treatment. Their self-perceived stress scores during the outbreak were also assessed. Methods: a prospective, observational study was performed in IBD patients on biologic treatment with stable clinical re-mission. Patients with both Crohn's disease (CD) and ulcerati-ve colitis (UC)were included. Patients filled in the IBDQ9 and the Perceived Stress Scale (PSS) electronically. To determine any changes, the results of the IBDQ9 during the outbreak were compared with the last IBDQ9 before the outbreak. Results: one hundred and six patients in clinical remission were included, with a median age of 42 years; 42 % were female and 77 % had CD. Median pre-COVID-19 IBDQ9 was 72.1 (66.5-80.12) and decreased to 69.2 (63.1-77.10) during the outbreak (p < 0.001). The median PSS score was 12 (9-19). There was a significant negative correlation between the PSS and the outbreak IBDQ9 (r =-0.66, p < 0.001). Re-gression analysis showed that the PSS score was associated with a lower IBDQ9 during the outbreak (p < 0.001). Conclusion: there was a negative impact of the COVID-19 outbreak on the HRQoL of IBD patients in remission, with higher self-perceived stress scores associated with a lower QoL. The COVID-19 outbreak may have long-term implica- tions for the HRQoL in these patients.